Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + autologous bone marrow mononuclear cell transplantation
- Development stage
- Unknown
- Lead developer
- Fuwai Hospital
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Oral, Intracoronary
01
Overview
This combination therapy consists of the HMG-CoA reductase inhibitor atorvastatin and autologous bone marrow mononuclear cell (MNC) transplantation. It was evaluated in a Phase 2 clinical trial led by the Chinese Academy of Medical Sciences, Fuwai Hospital, specifically for patients with anterior ST-elevated myocardial infarction (STEMI) and impaired left ventricular function. Atorvastatin, a small molecule statin, is administered at intensive doses to potentially enhance the therapeutic efficacy of the intracoronary-transferred MNCs. Beyond its primary role in cholesterol reduction, atorvastatin is studied in this context for its pleiotropic effects, which may improve stem cell survival, migration, and homing to the damaged cardiac tissue, thereby facilitating cardiac repair and regeneration following a myocardial infarction.
- Brand names
- Lipitor
- Other names
- atorvastatin + autologous bone marrow mononuclear cellsintensive atorvastatin + autologous bone marrow mononuclear cell transplantation
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + autologous bone marrow mononuclear cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + autologous bone marrow mononuclear cell transplantation.